deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT04603131

Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine

Phase-I Open Label, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Chikungunya Vaccine in Healthy Adults of 18 to 50 Years Age

Sponsor: Bharat Biotech International Limited

Conditions Chikungunya
Interventions Inactivated Chikungunya virus vaccine 10 mcg Inactivated Chikungunya virus vaccine 20 mcg Inactivated Chikungunya virus vaccine 30 mcg Placebo
Updated 4 times since 2020 Last updated: Oct 26, 2020 Started: Apr 17, 2017 Primary completion: Jan 30, 2018 Completion: Jul 30, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Chikungunya and is currently completed. Bharat Biotech International Limited leads this study, which shows 4 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE1

    First recorded

Apr 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bharat Biotech International Limited
Data source: Bharat Biotech International Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations